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Abstract 
Recent evidence suggests CML stem cells are insensitive to kinase inhibitors 
and responsible for minimal residual disease in treated patients. We 
investigated whether CML stem cells, in a transgenic mouse model of CML-
like disease or derived from patients, are dependent on Bcr-Abl. In the 
transgenic model, following re-transplantation, donor-derived CML stem cells 
in which Bcr-Abl expression had been induced and subsequently shut off, 
were able to persist in vivo and re-initiate leukemia in secondary recipients 
upon Bcr-Abl re-expression. Bcr-Abl knockdown in human CD34+ CML cells 
cultured for 12 days in physiological growth factors achieved partial inhibition 
of Bcr-Abl and downstream targets p-CrkL and p-STAT5, inhibition of 
proliferation and colony forming cells, but no reduction of input cells. The 
addition of dasatinib further inhibited p-CrkL and p-STAT5, yet only reduced 
input cells by 50%. Complete growth factor withdrawal plus dasatinib further 
reduced input cells to 10%, however the surviving fraction was enriched for 
primitive leukemic cells capable of growth in long-term culture initiating cell 
assay and expansion upon removal of dasatinib and addition of growth factors. 
Together these data suggest that CML stem cell survival is Bcr-Abl kinase 
independent and suggest curative approaches in CML must focus on kinase-
independent mechanisms of resistance.   
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Introduction 
 
In chronic myeloid leukemia (CML) the malignant clone is driven by the 
oncogene Bcr-Abl. Whilst there is strong evidence that Bcr-Abl is sufficient to 
induce CML-like disease in transduction/transplantation and transgenic 
murine models1-2 it is less clear that Bcr-Abl is always the first hit in CML in 
humans or that the disease in chronic phase is maintained by Bcr-Abl as the 
only driver mutation, rather than by additional genetic and/or epigenetic 
changes, as has been shown recently for Philadelphia-positive and negative 
acute lymphoblastic leukemia.3-4 Therefore comparisons between mouse 
models and primary CML should be interpreted with caution. In primary CML 
studies kinase inhibitors, imatinib5, dasatinib6, or nilotinib7 induced high rates 
of apoptosis. Similarly, in transduction/transplantation1 and transgenic1-2,8 
murine models of Ph+ B cell leukemia or CML, inhibition of Bcr-Abl kinase, by 
kinase inhibitors or by switching off transgene expression, resulted in 
proliferation arrest, apoptosis and complete remissions.  
Kinase inhibitors have transformed the natural history of CML by 
inducing cytogenetic and molecular responses in the majority of patients in 
chronic phase9 and resulting in transient deep responses in many cases of 
advanced disease.10 A proportion of CML cases develops drug resistance, 
with the incidence increasing in more advanced disease.11 In most cases the 
leukemic cells continue to express Bcr-Abl and often retain their dependence 
on the oncogene. For example, where the underlying mechanism for drug 
resistance is expansion of a clone expressing a Bcr-Abl kinase domain 
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mutation resulting in imatinib resistance, the leukemic cells retain sensitivity to 
second generation kinase inhibitors.7,12 
 Those working on CML now believe we are on a “pathway to cure”, 
however, this belief is tempered by the insensitivity of CML stem cells to 
kinase inhibitors.  We have consistently demonstrated that kinase inhibitors, 
imatinib13-14, nilotinib15-16, dasatinib17-18 and bosutinib19, although exhibiting 
potent anti-proliferative effects, are only weak inducers of apoptosis in CML 
stem and progenitor cells. In primitive stem/progenitor cells (CD34+38-) 
harvested from CML patients in durable complete cytogenetic response over 
5 years, Bcr-Abl transcripts show no suggestion of a downward trend over 
time.20 Furthermore, genomic PCR and PCR on individual LTC-IC colonies 
reveals that CML patients on imatinib who achieve complete molecular 
response remain Bcr-Abl positive.21-22 These in vitro and in vivo results, 
derived from primary human CML stem and progenitor cells, at least hint that 
CML stem cells may not be “oncogene addicted”. However, in these studies 
no conclusive evidence was provided that Bcr-Abl activity had been fully 
suppressed in the surviving cells and in particular in leukemic stem cells with 
repopulating potential, with many groups focused on issues of drug transport 
23-24
 and more potent kinase inhibitors.15-19 These data have recently been 
strengthened by a carefully conducted study which concluded that primary 
CML stem cells are insensitive to imatinib despite inhibition of Bcr-Abl.25 
Similarly, in transgenic mice multiple rounds of induction and reversion of Bcr-
Abl are possible2,8, suggesting long-term persistence of leukemic stem cells. 
However, as these studies were performed in primary recipients only there 
was no proof that transplantable stem cells were responsible for disease re-
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initiation. To address these critical points we employed complementary in vivo 
and in vitro approaches to determine whether Bcr-Abl activity is required for 
the survival of transplantable murine CML-like and primary human CML stem 
cells and conclude that this critical population is independent of Bcr-Abl 
kinase activity for survival. 
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Materials and methods 
 
Reagents.  
Dasatinib was obtained from Bristol-Myers Squibb (BMS). Stock solution 
(10mg/mL) in DMSO (Sigma-Aldrich) was prepared and stored in aliquots at -
20°C. 
Primary Cell Samples.  
Following informed consent, CD34+ cells were enriched from CML chronic 
phase samples at diagnosis and non-CML controls and cryopreserved.17  
In Vitro Cell Culture.  
HT1080 and 293FT cells were cultured in DMEM, K562, KCL22 and BaF3 
cells in RPMI-1640 medium, supplemented with 1% (v/v) 
penicillin/streptomycin (10,000µg/mL/10,000U/mL), 1% l-glutamine and 10% 
(v/v) fetal calf serum (all Invitrogen). IL-3 (10ng/mL, STEMCELL Technologies 
Inc.) was added to parental BaF3 cells. Primary CML cells were cultured in 
SFM17, supplemented with a high growth factor cocktail, 100ng/ml Flt-3 ligand 
and SCF and 20ng/ml each of IL-3, IL-6 (STEMCELL Technologies Inc.) and 
G-CSF (Chugai Pharma Europe Ltd.), growth factor cocktail for transduction, 
50ng/ml SCF, 100ng/ml TPO and Flt-3 ligand, physiological growth factor 
cocktail 0.2ng/ml SCF, GM-CSF and MIP-α, 1.0ng/ml G-CSF and IL-6, 
0.05ng/ml LIF (STEMCELL Technologies Inc.) or with no added growth 
factors. Primary mouse cells were cultured in SFEM supplemented with 
10ng/ml IL-3, IL-6 and mSCF (STEMCELL Technologies Inc.). 
 
Fluorescence in Situ Hybridization (FISH).  
FISH was performed as previously.17 
HAMILTON et al  CML STEM CELLS ARE NOT BCR-ABL DEPENDENT 
 8 
Lentivirus Production.  
The pHIV7-GFP transfer vector containing the shRNA expression cassette 
specific for two different splice forms of Bcr-Abl, pCMV-VSV-G and pCMV-
Hiv1 were provided by Dr. John Rossi.26 Transduction of K562 or KCL22 was 
performed at MOI 1-10 with 70-95% of the cells expressing GFP after 48hr. 
Primary human CD34+ cells were pre-incubated on retronectin (8ug/cm2) in 
medium containing growth factor cocktail for transduction for 2 days. 
Concentrated lentivirus was added twice for 24hr at MOI 40. 48hr later cells 
were FACS-sorted on GFP and cultured in medium containing physiological 
growth factors. 
Western Blotting and Flow Cytometry.  
Western blotting was performed17 using antibodies against Bcr-Abl/Abl, p-
CrkL, p-STAT5, Tubulin (Cell Signaling) and Actin (New England Biolabs Ltd 
and Sigma). Detection was by enhanced chemiluminescence (GE 
Healthcare/Amersham) using a horseradish peroxidase−linked secondary 
antibody. Bcr-Abl activity was determined as described previously.27 
Assessment of Apoptosis and CFSE Tracking of Cell Division 
Apoptosis and CFSE tracking were performed as previously described.16-17,28 
High Resolution Cell Cycle Analysis.  
High-resolution cell cycle analysis was performed using Ki-67 and 7AAD (BD 
BioSciences).29  
CFC and LTC-IC Assays.  
CFC and LTC-IC were performed as previously.28 
Q-PCR for Bcr-Abl and Abl-kinase Domain Mutation Analyses.  
HAMILTON et al  CML STEM CELLS ARE NOT BCR-ABL DEPENDENT 
 9 
Q-PCR was performed by Standardised EAC protocols30 and final results 
expressed according to the international scale.31 Kinase domain mutation was 
investigated by direct sequencing.32-33  
Q-PCR.  
Isolation of DNase-treated RNA was performed using RNeasy® Mini or Micro 
Kits (Qiagen). For colony PCR, cDNA was made using Taqman Gene 
Express Cells-to-CT Kit (Ambion). Bcr-Abl was detected using a real-time 
TaqMan assay (Eurogentec) or Evergreen (Web Scientific) using the ABI 
7500 Fast Real-Time PCR system (Applied Biosystems). GAPDH was used 
as control, setting the cut-off at 35 cycles. 
Mice and Genotyping.  
Genotyping of SCLtTA/Bcr-Abl dtg mice was described previously.2 Approval 
for the animal research was obtained from the local authorities of North-Rhine 
Westphalia, Germany. For first round transplantation 2x106 BM cells were tail 
vein injected into 12 week-old FVB/N CD45.2 mice after 8Gy irradiation. For 
secondary transplantation, 1.2x106 FACS-sorted CD45.1+ cells were injected 
into 9Gy irradiated FVB/N CD45.2 recipients. Mice were treated with 
cotrimoxazole (Ratiopharm) until 2 weeks after transplant. Peripheral blood 
(PB) was collected from the retro-orbital plexus. Tissues were fixed with 5% 
paraformaldehyde/PBS and paraffin-embedded. Sections from spleen were 
stained using N-acetyl-chloroacetate esterase (NACE). 
Flow Cytometry Analysis of Mice.  
After red cell lysis cells were stained with CD45.1, CD45.2, CD3, B220, Gr1, 
CD41, Ter119, IgG2a and IgG2b (BD BioSciences) and CD11b (Invitrogen). 
FACS analysis for Lineage-Sca-1+c-kit+ (LSK) cells was performed using red 
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cell-lysed BM stained with rat antibodies specific for CD3, CD4, CD8a, B220 
and Gr1 (Invitrogen), CD11b, Ter119. LSK cells were stained using CD117 (c-
kit) and Sca-1 (BD BioSciences). Isolation of lineage negative cells was 
performed using MACS mouse lineage depletion kit (Miltenyi Biotec Inc.). For 
purification of LSK cells lineage negative cells were stained with rat antibodies 
specific for CD3, CD4, CD8a, B220 and Gr1 (Invitrogen), CD11b, Ter119, 
CD117 (c-kit) and Sca-1 (BD BioSciences) and FACS-sorted. 
Statistical Analysis.  
Error bars represent SEM. Statistical analyses were performed using two-
tailed student’s t-test. A level of P less than or equal to 0.05 was taken to be 
statistically significant. 
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Results 
 
Leukemic stem cells retain their transplantation and leukemogenic potential 
following complete reversion of Bcr-Abl. We previously described an inducible 
transgenic mouse model of CML in which p210-Bcr-Abl expression is targeted 
to stem and progenitor cells of murine bone marrow (BM) using the tet-off 
system.2,8 Upon tetracycline withdrawal Bcr-Abl expression is induced and 
mice demonstrate leukocytosis, splenomegaly and myeloid hyperplasia. The 
disease is transplantable using Bcr-Abl+ unfractionated (uf) BM or LSK cells 
and can be reverted following tetracycline treatment or to a much lesser 
extent using imatinib.8 In both transgenic and primary transplant recipients the 
CML-like disease is fatal after 29-122 days.2,8  
Here we used the CD45.1/45.2 system to discriminate donor and host 
cells in a transplantation setting and were thus able to serially transplant the 
initially leukemic cells after abrogation of Bcr-Abl expression and reversion of 
the CML phenotype (Figure 1Ai). SCLtTA/Bcr-Abl double transgenic (dtg) BM 
cells from CD45.1 donors were transplanted into 8Gy sublethally irradiated 
CD45.2 recipients (n=12). Wild type (wt) CD45.1 donors were used as 
controls (n=12). An alternative approach would have been to use dtg mice as 
donors and to maintain one cohort on and the other one off tetracycline 
throughout the experiment. This was considered but decided against in view 
of concern that tetracycline might lead to undesired effects on either normal or 
leukaemic haemopoiesis. Recipient mice were maintained off tetracycline to 
induce Bcr-Abl expression as shown previously.2,8 PB analysis on day 21 
confirmed that dtg recipient mice had developed disease and this was 
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confirmed in BM and spleen on day 25 when mice were sacrificed. At this 
time-point donor BM LSK showed a slight but significant 1.2-fold expansion 
compared to controls (Supplemental Figure 1A-G).  
Tetracycline was then administered to the remaining mice to abrogate 
Bcr-Abl expression and revert the phenotype (Figure 1Aii). By day 41 on PB 
sampling the disease had been completely reverted with no difference 
between dtg and controls (Supplemental Figure 1Hi-ii) and this was confirmed 
at the time of sacrifice on day 48, with no evidence of leukemia in BM or 
spleen (Supplemental Figure 1I-M). Strikingly, the percentages of mature and 
immature granulocytic donor cells decreased to control levels in dtg BM and 
spleen upon Bcr-Abl abrogation (compare Supplemental Figure 1B-C, I-J), 
showing that proliferation and survival of mature cells are affected by Bcr-Abl 
abrogation. Conversely, BM LSK donor cells had continued to increase by 
equivalent amounts in control and dtg mice (Supplemental Figure 1M) 
suggesting that dtg donor LSK cells showed similar chimerism dynamics as 
controls. Bcr-Abl was neither detectable in total BM nor spleen cells, nor in 
FACS sorted CD45.1+ BM cells from either cohort. Histology of spleen 
showed no evidence of leukemic infiltration and there was no evidence of 
splenomegaly. In order to assess potential residual Bcr-Abl expression in 
reverted LSK cells, we FACS sorted these cells from a cohort of primary, 
transgenic mice that had either been induced for 3 weeks or reverted for an 
additional 6 weeks. Analysis of BM, spleen and PB confirmed neutrophilia and 
splenomegaly restricted to induced, but not reverted dtg or control mice 
(Supplemental Figure 2A+B). RT-PCR using LSK cells showed a >96% 
reduction of Bcr-Abl expression in reverted mice back to control levels 
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(Supplemental Figure 2C). To assess Bcr-Abl activity we performed Western 
blot using lineage negative BM cells from mice that had either been induced 
for 4 weeks (Supplemental Figure 2E) or mice that had been reverted for 68 
days after a 3 week induction period (Supplemental Figure 2F). Level of CrkL 
phosphorylation was increased upon induction of Bcr-Abl (Supplemental 
Figure 2E) but was decreased to control level upon reversion (Supplemental 
Figure 2F). These results confirmed that by administration of tetracycline the 
leukemic phenotype had been completely reverted. 
As a final step, FACS sorted, BM derived, CD45.1+ cells from each 
cohort were re-transplanted, at 1.2x106 cells per mouse, into 9Gy sublethally 
irradiated, secondary recipients (CD45.2+, n=5/5, Figure 1Aiii). These mice 
were maintained off tetracycline to re-induce Bcr-Abl expression to determine 
whether cells with oncogenic potential had survived the reversion period. PB 
analyses 34 days after transplantation again showed an increased donor to 
host cell ratio, increasing percentages of donor granulocytes (Figure 1Bi) and 
increased numbers of granulocytes (Figure 1Bii). After a further 35 days the 
secondary recipients were sacrificed at 69 days after re-transplantation and 
re-induction of Bcr-Abl expression. CD45.1+ dtg donor cells had engrafted in 
BM and spleen (Figure 1C-D). Although the phenotype was weaker than in 
the primary recipients, there was still significant expansion of immature 
myeloid donor cells in BM and spleen (Figure 1C-D). Development of 
splenomegaly was observed, but did not reach statistical significance (Figure 
1E), unless the dtg mice were corrected for loss of body weight upon disease 
development. In addition, disruption of spleen morphology and myeloid cell 
infiltration of the spleen were clearly observed in dtg mice (Figure 1F). There 
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was a non-significant trend towards an increase of dtg donor BM LSK 
compared to control LSK cells (2.1 fold increase, Figure 1G). Bcr-Abl was 
expressed in BM and spleen of all secondary dtg recipients (Figure 1H). As an 
alternative to switching off Bcr-Abl transgene expression in transplanted 
CD45.1 dtg LSK we treated total BM and LSK cells with dasatinib. Western 
blot showed that p-CrkL level was increased in total BM and LSK of Bcr-Abl 
expressing cells but was completely reverted upon 100nM dasatinib treatment 
(Figure 1I). In addition we demonstrated that dasatinib treatment significantly 
induced apoptosis in leukemic total BM and mature Gr1 positive cells, 
whereas Bcr-Abl expressing dtg LSK were comparatively resistant (Figure 1J).  
 
Partial Bcr-Abl knockdown inhibits proliferation of CML CD34+ cells. Recently 
Shah et al argued for evaluation of more than one endpoint for inhibition of 
Bcr-Abl to ensure coverage of an adequate dynamic range.34 Measurement of 
inhibition of phosphorylation of STAT5 and CrkL by flow cytometry and 
Western blotting was therefore optimised in BaF3 cells expressing Bcr-Abl 
(Supplemental Figure 3A-C). 150nM dasatinib reduced phosphorylation of 
both CrkL and STAT5 to the baseline seen in parental BaF3 cells, with no 
effect on Bcr-Abl T315I mutant and no additional effect with increasing 
concentrations of dasatinib (Supplemental Figure 3A-C). Previous data using 
lentiviral mediated shRNA delivery confirmed efficient and specific knockdown 
of Bcr-Abl in Ph+ cell lines expressing B3A226,35 (Supplemental Figure 3D-E). 
Here Bcr-Abl was knocked down in CML CD34+ cells expressing B3A2, 
cultured in serum free medium (SFM) supplemented with physiological growth 
factors, and viral transduction of the most primitive CD34+38- population 
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verified (Supplemental Figure 4A-B). To measure the extent of Bcr-Abl 
knockdown, transduced CD34+ CML cells were FACS sorted. Q-PCR 
confirmed 56% specific downregulation of Bcr-Abl mRNA (Figure 2A) and 
Western blot showed clear reduction in Bcr-Abl protein level (48% by 
densitometry) (Figure 2B). We then sought to demonstrate inhibition of Bcr-
Abl downstream targets. In primary CML CD34+ cells 150nM dasatinib was 
sufficient to reduce p-CrkL27 and p-STAT5 to the same level (described as 
baseline) as non-CML CD34+ cells (Bcr-Abl-negative control; Figure 2C-D). In 
Bcr-Abl knockdown CML cells inhibition of phosphorylation of both CrkL and 
STAT5 was observed in CD34+ and CD34+38- cells by flow cytometry (gated 
on GFP+ cells) (Supplemental Figure 4C), and in CD34+ cells for STAT5 by 
Western blotting (Figure 2B), although the level of inhibition was not as 
profound as seen with dasatinib. 
While sh-Control expressing cells were able to expand ~3-fold over 12 
days in the presence of physiological growth factors, sh-Bcr-Abl cells showed 
little expansion (Figure 3A), with some induction of apoptosis (Figure 3B). To 
examine the effect of Bcr-Abl knockdown on survival/proliferation of functional 
CML stem and progenitor cells, GFP+ cells were plated into colony forming 
cell (CFC) and long-term culture-initiating cell (LTC-IC) assays (Figures 3C, 
D). Bcr-Abl knockdown resulted in 47 and 71% reduction in CFC and LTC-IC 
colonies respectively. Q-PCR on single colonies for Bcr-Abl and Western 
blotting for p-CrkL on pooled colonies confirmed Bcr-Abl inhibition in cells 
expressing sh-Bcr-Abl (Figures 3E and F).  
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A proportion of CML CD34+ cells is sensitive to enhanced levels of Bcr-Abl 
inhibition. To determine whether CML CD34+ cells would be susceptible to 
further inhibition of Bcr-Abl activity, GFP+ knockdown and control cells were 
cultured in physiological growth factors in the presence and absence of 
150nM dasatinib for 12 days, with fresh medium and dasatinib replaced on 
days 4 and 8. When GFP+ CML CD34+ cells were exposed to 150nM 
dasatinib (Figure 2E-F), further reductions in phosphorylation of CrkL and 
STAT5, over those seen with sh-Bcr-Abl, and to previously described baseline 
levels, were seen, confirming complete inhibition of Bcr-Abl kinase activity. 
For dasatinib, cell counts on days 4, 8 and 12 illustrated a sharp reduction in 
cell numbers evident by day 4, irrespective of Bcr-Abl knockdown (Figure 3A). 
Most interestingly, about 50% of input cells survived combined partial Bcr-Abl 
knockdown and dasatinib treatment for 12 days, indicating that, at least in 
medium supplemented with physiological growth factors, a proportion of 
CD34+ cells can survive without Bcr-Abl kinase activity. However, with the 
limited number of cells available it was not feasible to confirm complete Bcr-
Abl inhibition at all time-points, neither was it possible to examine whether, as 
expected, surviving cells were enriched for primitive stem cells. 
 
Complete Bcr-Abl kinase inhibition is achievable at the stem/progenitor cell 
level. To investigate in more detail whether CML stem/progenitor cells would 
be susceptible to complete inhibition of Bcr-Abl activity, CML CD34+ cells 
were cultured in SFM, in the presence or absence of dasatinib, which was 
replaced with fresh medium on days 4 and 8. Following preliminary 
experiments (Supplemental Figure 5A-D and Supplemental Table 1), these 
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cells were cultured without growth factors to exclude any additional survival 
signals. In the remaining viable cells on days 4, 8 and 12 Bcr-Abl activity was 
fully inhibited as demonstrated by complete inhibition of p-CrkL by flow 
cytometry and by Western blotting (Figure 4A-B). Since genuine CML stem 
cells likely represent a small fraction of total CD34+ cells, previous work has 
focused on those CD34+ cells that remain quiescent in culture by tracking cell 
division with CFSE.16-17,28 Here the level of inhibition of p-CrkL by continuous 
exposure to dasatinib 150nM was determined on days 4, 8 and 12 for viable 
CML CD34+ cells that remained undivided in culture or entered cell divisions 
1, 2 or 3. The level of inhibition of p-CrkL achieved across the entire time 
course showed no significant difference for primitive undivided CD34+ CML 
cells as compared to more mature cells able to enter division (Figure 4C and 
Supplemental Table 2). Inhibition of p-STAT5 by dasatinib gave a very similar 
profile as seen for p-CrkL (Supplemental Figure 6A). Although no significant 
differences were detected in levels of inhibition between undivided and cells in 
divisions 1-3, we repeated the experiment including a higher concentration of 
dasatinib to ensure that inhibition of p-CrkL was complete (Figure 4D). 
Critically, residual levels of p-CrkL were equivalent for 150 and 1000nM 
dasatinib. 
 
The most primitive, quiescent CML stem and progenitor cells are independent 
of Bcr-Abl kinase for survival. In the mouse haemopoietic stem cells can be 
selected to near purity (1 in 2) based on surface markers. However, this is not 
yet possible for normal or leukemic human stem cells. The human stem and 
progenitor compartment should therefore be considered as a continuum and 
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not made up of discrete populations. Here we have combined accepted 
surrogate markers for primitive cells based on phenotype, CFSE retention, 
absence of Ki-67 staining, expansion kinetics, CFC, CFC re-plating and LTC-
IC to demonstrate which CML cells are growth factor and Bcr-Abl kinase 
independent. Over the same 12 days, in the absence of growth factors, 
untreated CML CD34+ cells expanded by approximately 4-fold, in keeping 
with their autocrine production of cytokines36-37, whereas with 150nM 
dasatinib viable cells decreased to 10% of input (Figure 5A). CFSE profiling 
demonstrated that even in the absence of growth factors and with addition of 
dasatinib, CML CD34+ cells were able to enter divisions 1 and 2, with a few 
cells progressing as far as division 3 (Figure 5B). The untreated control CML 
CD34+ cells proliferated more actively, with the majority of cells found in 
divisions 3 and 4. Although CFSE profiling confirmed that most CML CD34+ 
cells had gone through one or more divisions in the presence of dasatinib, by 
day 12, >85% of residual cells had become quiescent as demonstrated by low 
Ki-67 staining (Figure 5Ci-ii). To confirm that the viable residual cells were 
functional and not irreversibly arrested or senescent, on day 12, both 
experimental arms were washed and re-established in culture in SFM with 
added growth factors. Ki-67 and 7AAD analysis confirmed that the majority of 
CML CD34+ cells that had been cultured in the absence of growth factors and 
in the presence of dasatinib at 150nM for 12 days rapidly entered cell division 
with only 6% remaining Ki-67 low after a further 7 days culture (Figure 5Ciii-iv). 
The pattern of Ki-67 and 7AAD staining was very similar for the untreated 
control (Figure 5Ciii-iv). Further confirmation that almost all the dasatinib 
treated cells entered cell division again by day 7 was provided through CFSE 
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staining (Figure 5Di-ii). Although the residual quiescent fraction was less than 
10% in both arms, the dasatinib treated cells expanded more slowly over 7 
days with a total 5-fold expansion compared to untreated control, 17-fold 
expansion (Figure 5E). Both populations showed complete reactivation of Bcr-
Abl kinase activity, as measured by p-CrkL staining (data not shown). 
Enrichment for primitive cells was confirmed by CFSE retention, phenotyping 
for CD34 and CD133 (Figure 5F) and by residual CFC, CFC re-plating 
potential and LTC-IC activity in the dasatinib treated cells (Figure 5G-K). 
Taking into account that the untreated cells expanded by 4-fold and the 
dasatinib treated cells decreased to 10% of input, the final frequency of LTC-
IC was 10-fold higher in the dasatinib treated versus untreated arms. The 
residual viable cells present at day 12 were also confirmed to express single 
copy Bcr-Abl by D-FISH (Figure 5L), to express Bcr-Abl by Q-PCR 
(Supplemental Figure 6B) and showed no evidence of mutation by direct 
sequencing of the kinase domain, thus confirming that these cells were 
leukemic and that their dasatinib resistance could not be explained by 
mutation. 
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Discussion 
 
The discovery that Bcr-Abl exhibited oncogenic properties38 and was sufficient 
to induce CML-like disease in mice1 provided clear evidence that Bcr-Abl was 
the key initiating event in CML. However, for many years investigators were 
sceptical that a tumour would remain dependent on the initiating oncogene in 
view of accumulation of additional genetic and epigenetic events occurring 
over time. The early studies with imatinib, a relatively selective Bcr-Abl 
inhibitor, resulted in a genuine paradigm shift with many drug discovery efforts 
now focused on single oncogenic lesions and the belief that a variety of 
tumours may depend on the driver oncogene. This concept of oncogene 
addiction was further strengthened when CML patients with blast crisis, a 
cancer more akin to solid tumours, also showed dramatic responses to 
imatinib, providing compelling proof that even these genetically complex 
cancers can remain dependent on the initiating driver mutation. The 
phenomenon of oncogene addiction, whilst well recognised, is poorly 
understood. Despite genetic complexity cancer cells become dependent, by 
an unknown mechanism, on a single oncoprotein-driven signaling cascade, 
which, if disrupted acutely, results in cell cycle arrest and apoptosis. There is 
on-going debate regarding whether this is a passive process resulting from 
withdrawal of pro-survival signaling, or an active process driven by 
accumulation of pro-apoptotic signals.39-41 Furthermore, responses of tumours 
to oncogene inhibition are highly variable and dependent on the cellular and 
genetic context. These responses in human cancer are paralleled in 
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transgenic murine models in which oncogene inactivation gives the 
impression of tumour regression, yet upon oncogene reactivation the disease 
can recur.2,8,42-43  
For CML there is now convincing evidence that the malignant stem cell 
population is intrinsically resistant to kinase inhibitors13-14,16-19,25 and behaves 
quite differently to the bulk population of more mature cells that are oncogene 
addicted. This also appears to be the case in the transgenic mouse model in 
which Bcr-Abl+ mature myeloid cells undergo apoptosis in response to in vitro 
dasatinib treatment, with the LSK population being relatively resistant.  In vivo 
Bcr-Abl is likely induced in approximately 50% of donor CD45.1+ long-term 
repopulating HSC, 20% of LSK and 17% of lin+ c-kit+ cells based on a 
comparable model using the SCL 3’ enhancer44 and unpublished work (Ravi 
Bhatia). This fits well with our data showing that upon reversion of the 
leukemic phenotype the proportion of donor CD45.1+ cells returns to those of 
control mice rather than being eliminated altogether. We considered that 
reversion of disease in this model may either occur because transgenic stem 
cells undergo apoptosis in response to oncogene inactivation39-41 or because 
they revert back to the behaviour of normal stem cells and no longer produce 
excess numbers of more mature myeloid cells. Our data show that despite 
complete reversion of disease the leukemic LSK persist, but proliferate less, 
and do not undergo apoptosis upon oncogene withdrawal. These surviving 
LSK, in which Bcr-Abl expression has been suppressed by >96%, are capable 
of re-initiating disease following secondary transplantation and re-induction of 
Bcr-Abl expression. 
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These results with the transgenic CML model were closely replicated by our 
work on primary CML cells.  Functional CML stem and progenitor cells were 
able to survive in vitro for prolonged periods of time despite complete 
oncogene inactivation and withdrawal of cytokines. Using similar experimental 
approaches to Corbin et al25, we made every effort to demonstrate that in the 
surviving CML stem cells Bcr-Abl activity was completely shut off. We further 
confirmed that the drug resistant population belonged to the leukemic clone, 
was enriched for primitive cells and showed neither Bcr-Abl amplification nor 
kinase domain mutation, further mechanisms that might explain their 
resistance.  
Taken together, these results have firmly shifted our focus towards Bcr-
Abl kinase independent resistance mechanisms that might involve “stem cell 
phenotype”, “stem cell signaling” or other survival pathways that are either not 
suppressed by or are induced by kinase inhibitors and are the subject of 
current investigation by ourselves and others. These involve approaches to 
reverse CML stem cell quiescence by interfering with Foxo transcription factor 
activity using inhibitors of TGFβ, BCL6 activity using a retro-inverso peptide 
inhibitor45-46 or PML activity using arsenic trioxide; to inhibit self-renewal in 
favour of differentiation through inhibition of WNT or hedgehog signalinglaing; 
to mobilise CML stem cells from the niche using CXCR4 antagonists; to inhibit 
JAK signaling; to inhibit kinase inhibitor induced autophagy; to activate PP2A; 
or to exploit differences in epigenetic regulation between normal and CML 
stem cells. These approaches have been comprehensively reviewed in the 
EHA Education Book 2011.47  
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When considering mechanisms of resistance it is important to consider 
both the kinase activity of Bcr-Abl and other non-kinase domains of Bcr-Abl 
that might confer resistance. Using a mouse genetics approach, Chen et al 
were able to reveal Alox5 as a target whose expression was dependent on 
Bcr-Abl expression, but not modulated by kinase inhibition.48 To take account 
of this possibility we used the combination of Bcr-Abl knockdown with kinase 
inhibition. However, since we were unable to achieve >50% inhibition of Bcr-
Abl using an shRNA specific for the breakpoint and believe that this is not 
technically possible in primary CML stem cells at this time, we have not 
formally been able to exclude on-going signaling via non-kinase Bcr-Abl 
motifs or proteins within the Bcr-Abl interactome such as Jak2, within the 
primary cells.49-50 Although complete abrogation of Bcr-Abl expression was 
achieved in the transgenic mouse model, we accept that relatively short-term 
transgenic expression may not allow for further genetic or epigenetic changes 
that likely occur in the primary setting that might affect the degree of 
oncogene addiction and would again suggest caution when comparing mouse 
models with human disease. Future efforts towards cure in CML patients who 
are responding well to kinase inhibitors, but continue to show evidence of 
minimal residual disease, should focus on understanding the mechanisms of 
proliferation arrest and dormancy upon oncogene inactivation in the CML 
stem cell population and aim to target Bcr-Abl kinase independent survival 
pathways that remain active in these cells or are activated upon kinase 
inhibition. In the latter scenario it is possible that kinase inhibition will be 
required alongside a second agent to achieve synthetic lethality. Similarly in 
solid tumours driven by a single oncogene and sustained by cancer stem cells 
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an enhanced understanding of tumour dormancy will be a critical step to 
uncovering novel targets in this drug resistant population. 
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Figure 1. CML stem cells retain transplantation and oncogenic capacity 
following Bcr-Abl reversion. (A) 8Gy irradiated CD45.2+ mice transplanted 
using  unfractionated (uf) CD45.1+ BM cells isolated from SCLtTA/Bcr-Abl dtg 
or wt controls (n=12/12). Bcr-Abl expression in recipient mice was controlled 
by absence (expression) or presence (no expression) of tetracycline in 
drinking water. Bcr-Abl expression was induced after transplantation for 25 
days and the phenotype analysed in dtg and controls (n=3/3) by FACS of BM 
and spleen cells, spleen weight and histology, ratio of donor:host LSK cells 
and Bcr-Abl expression (i). Bcr-Abl expression was reverted for 48 days and a 
cohort of remaining mice (n=4/4) analysed (ii). BM cells from reverted dtg and 
controls were re-transplanted using CD45.1+ FACS-sorted cells (n=5/5). Bcr-
Abl expression was re-induced and the phenotype was assessed 69 days 
after re-transplantation (iii). (Bi-ii) PB was analysed in CD45.1+ re-
transplanted and re-induced mice 34 days after secondary transplantation.  
FACS of BM (C) and spleen (D). Mean percentages of donor cells (CD45.1+), 
recipient cells (CD45.2+), granulocytes (Gr1+/CD11b+), immature granulocytes 
(Gr1low/CD11b+), donor granulocytes (Gr1+/CD45.1+), immature donor 
granulocytes (Gr1low/CD45.1+), B cells (B220+), T cells (CD3+) or erythroid 
cells (Ter119+). Spleen weights upon autopsy (E), spleen histology (F), 
donor:host ratio within BM LSK (G) and Bcr-Abl expression in secondary 
recipients (H). BM and LSK cells from 4 week induced dtg and control mice 
were cultured with either 50nM dasatinib, 100nM dasatinib or DMSO for 48hr. 
The level of p-CrkL was measured by Western blotting (I). Apoptosis in total 
BM, Gr1 and LSK cells was assessed by Annexin V staining in cells from 4 
week induced dtg (n=7) and control (n=5) mice that were treated for 48hr 
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using 100nM dasatnib or DMSO (J). Histologic analyses of spleen were 
performed using NACE-stain and are shown at magnifications of x10 (insets) 
and x20. Shown is one representative spleen histology from each group. 
LF=Lymphoid Follicle. Data represented as mean ± SEM. *p<0.05. 
 
Figure 2.  Bcr-Abl knockdown and dasatinib treatment of CML cells in 
physiological growth factors. CD34+ CML cells were infected with sh-Bcr-
Abl or sh-Control. 48hr following second infection cells were sorted for GFP, 
RNA and protein extracted and relative expression of Bcr-Abl measured by Q-
PCR (n=5, p=0.0004) (A) and Bcr-Abl and p-STAT5 by Western (n=1) (B). 
CD34+ non-CML (n=3) and CML cells (n=3) were cultured in SFM ± growth 
factors ± 150nM dasatinib. 24hr following treatment p-CrkL (C) and p-STAT5 
(D) were measured by flow cytometry. Lentivirally infected CD34+ cells (n=3) 
were cultured in physiological growth factors and treated ± 150nM dasatinib. 
24hr following treatment p-CrkL (E) and p-STAT5 (F) were measured in 
infected cells (gated on GFP) cells by flow cytometry.   
 
Figure 3. Functional analysis of CML CD34+ cells following Bcr-Abl 
knockdown ± dasatinib. (A) Proliferation of GFP+ sorted cells treated ± 
150nM dasatinib in physiological growth factors over 12 days (n=3). (B) 
Apoptosis measured in infected cells (gated on GFP) by annexin V and 
viaprobe (n=2). (C) CFC (n=4, p=0.025) and LTC-IC assays (n=1) (D) Bcr-Abl 
levels were measured by Q-PCR on colonies from CFC assay (n=7 colonies 
for sh-scrambled and 9 colonies for sh-Bcr-Abl) (E). The level of total p-CrkL 
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was measured by Western blotting on pooled colonies from CFC assay (n=1) 
(F).  
 
Figure 4. Complete Bcr-Abl inhibition is achieved by dasatinib within 
primitive subpopulations of CML cells. CFSE stained CD34+ CML cells 
(n=3) were cultured in SFM ± 150 or 1000nM dasatinib for 12 days. (A) The 
levels of total p-CrkL were measured by flow cytometry and (B) by Western 
blotting at day 12. p-CrkL was also measured within each cell division after 
treatment with either 150 (C) or 1000nM dasatinib (D). 
  
Figure 5. A primitive subset of CD34+ CML cells survives complete Bcr-
Abl inhibition in growth factor free medium for 12 Days. (A) CD34+ CML 
cells (n=3) were cultured in SFM ± 150nM and viable cell counts performed on 
days 4, 8 and 12 and (B) percentages of cells residing within each cell division 
determined by CFSE staining. Following 12 days, cells were washed with 
PBS, added to CFC and LTC-IC assays, cultured in SFM plus high growth 
factor cocktail for 7 days. At day 7 Ki-67/7AAD (C) and CFSE (D) were 
measured by flow cytometry and viable cell counts performed (E). The relative 
increase in CD34+CD133+CFSEhigh was calculated (n=3, p=0.001) (F) and 
the numbers of CFC (n=7, p=0.048) (G) and LTC-IC (n=3, p=0.025) (H) per 
1000 cells at day 12 were calculated. The changes in CFC (I) CFC re-plated 
(n=2) (J) and LTC-IC (K) numbers as compared to baseline cells (1.0) were 
also calculated. (L) The presence of Bcr-Abl (denoted by the white arrows) 
was measured by D-FISH in the remaining CML cells following the 12 day 
time course. A representative profile from (i) non-CML CD34+ cells at 
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baseline, (ii) untreated CD34+ CML cells and (iii) 150nM dasatinib-treated 
CD34+ cells is demonstrated. 
 
 
 
 
